Loading
Resminostat is an oral drug of the HDAC inhibitor class, proposed for advanced mycosis fungoides and Sézary syndrome, two cutaneous T-cell lymphomas. Europe's medicines committee said no to it in May 2025, so it is not authorised.
Resminostat (Kinselby, applicant 4SC AG, orphan designation) was proposed for the treatment of patients with advanced-stage mycosis fungoides and Sézary syndrome. The CHMP adopted its opinion on 22 May 2025 and the opinion status on the EMA product page is negative, so there is no EU marketing authorisation. The active substance is resminostat mesilate; the EMA lists the therapeutic area as mycosis fungoides. The corpus's approved HDAC inhibitors in cutaneous T-cell lymphoma are romidepsin and vorinostat (target page `hdac`).
Oral histone deacetylase inhibitor proposed for advanced-stage mycosis fungoides and Sézary syndrome; the EMA's committee adopted a negative opinion on the marketing application (EMA product page). Connects to Histone deacetylases (HDAC).
1.Resminostat slips into a pocket on Histone deacetylases (HDAC).
Compare all products across the US, EU, UK, Japan, China and Australia →
CHMP negative opinion on Kinselby (resminostat) for advanced mycosis fungoides and Sézary syndrome source
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Resminostat" OR ABSTRACT:"Resminostat" OR TITLE:"Kinselby" OR ABSTRACT:"Kinselby" OR TITLE:"resminostat" OR ABSTRACT:"resminostat" OR TITLE:"resminostat mesilate" OR ABSTRACT:"resminostat mesilate" OR TITLE:"4SC-201" OR ABSTRACT:"4SC-201") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Resminostat, not a curated reading list.
Shares Histone deacetylases (HDAC), Romidepsin, Sezary syndrome, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares Romidepsin, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares Sezary syndrome, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares Histone deacetylases (HDAC), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares Sezary syndrome, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares Sezary syndrome, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares Sezary syndrome, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares Romidepsin, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).